Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-03: sacituzumab govitecan versus physician's choice chemotherapy in previously untreated advanced or metastatic triple-negative breast cancer
jRCT2041220122Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival. Started Mar 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2041220122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220122.